格隆汇8月20日丨华森制药(002907.SZ)公布，公司于近日收到重庆市药品监督管理局颁发的《药品生产 许可证》(许可证编号：渝20150018)，本次变更主要涉及增加生产范围(仅限注册申报使用)、核减受托 生产(仅限注册申报使用)和新增受托生产。 ...

Core Points - Chongqing Huasen Pharmaceutical Co., Ltd. has received approval from the Chongqing Municipal Drug Administration for the re-registration of two drugs: Pediatric Throat Granules and Diammonium Glycyrrhizinate for Injection [1][2][6] Group 1: Drug Registration Information - Pediatric Throat Granules are indicated for clearing heat and relieving throat pain, used for children with symptoms such as sore throat, cough with phlegm, and acute pharyngitis [2][4] - Diammonium Glycyrrhizinate for Injection is used for acute and chronic viral hepatitis with elevated alanine aminotransferase (ALT) levels, exhibiting anti-inflammatory and hepatoprotective effects [3][5] Group 2: Market Context - The pediatric traditional Chinese medicine market has reached a record high of 18.3 billion yuan in 2024, with pediatric cold medications accounting for 37.23% and cough medications for 34.40% of the market share [4] Group 3: Company Impact - The approval of the re-registration will ensure the normal production and sales of the drugs, allowing the company to maintain high product quality [6]

Core Viewpoint - Huason Pharmaceutical has received drug re-registration approval for two products, indicating a positive development in its product portfolio and market presence [1][2]. Group 1: Product Details - The company received approval for "Pediatric Throat and Tonsil Granules," which is used for treating symptoms like sore throat and cough in children [1]. - The second product, "Injectable Glycyrrhizin Ammonium," is indicated for acute and chronic viral hepatitis with elevated ALT levels, showcasing its comprehensive liver protection effects [2]. Group 2: Market Insights - The pediatric traditional Chinese medicine market in China is projected to reach 18.3 billion yuan in 2024, with pediatric cold medications accounting for 37.23% and cough medications for 34.40% of the market share [1]. - The approval of these products aligns with the growing demand for pediatric medications, particularly in the context of rising sales in the sector [1]. Group 3: Regulatory and Quality Assurance - The approval ensures the normal production and sales of the mentioned drugs, with the company committing to strict quality control measures [2]. - The injectable glycyrrhizin ammonium has been included in several national and international liver disease management guidelines, reinforcing its credibility and market position [2].

Group 1 - The company, Huason Pharmaceutical, announced the receipt of two drug re-registration approval notices from the Chongqing Drug Administration [2] - The approved drugs include Pediatric Pharyngeal Tonsil Granules and Injection Glycyrrhizic Acid Disodium [2]

一、《药品再注册批准通知书》主要信息 （一）小儿咽扁颗粒 药 品 通 用 名 称：注射用甘草酸二铵 英 文 名 / 拉 丁 名：Diammonium Glycyrrhizinate for Injection 受 理 号：CYHZ2540457 渝 证券代码：002907 证券简称：华森制药 公告编号：2025-063 重庆华森制药股份有限公司 关于公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监 督管理局（以下简称"市药监局"）核准签发的关于公司 2 个药品的《药品再注 册批准通知书》。现将相关情况公告如下： | 药 | 品 | 通 | | 用 | 名 | 称：小儿咽扁颗粒 | | --- | --- | --- | --- | --- | --- | --- | | 受 | | | 理 | | | 号：CYZZ2417666 渝 | | 通 | 知 | | 书 | | 编 | 号：2025R075783 | | 剂 | | | | | | 型：颗粒剂 | ...

Core Insights - The stock price of Huason Pharmaceutical (002907) closed at 18.01 yuan on August 13, 2025, with a slight increase of 0.06% [1] - The company reported a total revenue of 239 million yuan for Q1 2025, reflecting a year-on-year growth of 4.62% [1] - The net profit attributable to shareholders was approximately 40.36 million yuan, showing a marginal increase of 0.01% year-on-year [1] Financial Performance - Total revenue for Q1 2025: 239 million yuan, up 4.62% year-on-year [1] - Net profit attributable to shareholders: 40.36 million yuan, up 0.01% year-on-year [1] - Non-recurring net profit: 37.67 million yuan, up 1.08% year-on-year [1] - Current ratio: 5.198, Quick ratio: 4.589, Debt-to-asset ratio: 12.95% [1] Market Activity - The trading volume was 120,400 lots, with a transaction amount of 216 million yuan [1] - Main funds experienced a net outflow of approximately 16.80 million yuan, accounting for 7.78% of the transaction amount [1] - Small orders saw a net inflow of approximately 21.41 million yuan, representing 9.92% of the transaction amount [1] Company Background - Huason Pharmaceutical was established in 1996 and is located in Chongqing, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of approximately 4.18 billion yuan and a paid-in capital of 777 million yuan [1][2] - The legal representative of the company is You Hongtao [1] Investment and Intellectual Property - The company has made investments in 12 enterprises and participated in 4,250 bidding projects [2] - It holds 204 trademark registrations and 135 patents, along with 210 administrative licenses [2]

Group 1 - The core issue involves tax self-inspection results disclosed by two companies, Daon Co., Ltd. and Huason Pharmaceutical, due to discrepancies in the tax treatment of convertible bond interest expenses [1][3][7] - Daon Co., Ltd. needs to pay a total of 16.15 million yuan, which includes 11.87 million yuan in corporate income tax and 4.27 million yuan in late fees [3][4] - Huason Pharmaceutical is required to pay a total of 10.02 million yuan, comprising 7.17 million yuan in corporate income tax and 2.84 million yuan in late fees [1][7][8] Group 2 - Both companies confirmed that the tax payment issues do not involve prior accounting errors and will not require restatement of previous financial data [4][8] - The tax payments will impact the net profit attributable to shareholders for the year 2025, with Daon Co., Ltd. expecting a reduction of 16.15 million yuan and Huason Pharmaceutical anticipating a reduction of 10.02 million yuan [4][8] - The companies have emphasized their commitment to enhancing supervision and management of tax-related matters to protect the interests of shareholders [8]

Core Viewpoint - The company is actively expanding its product offerings and market presence, particularly in traditional Chinese medicine and innovative pharmaceuticals, while achieving significant milestones in international market approvals and research advancements [2][3][5]. Group 1: Company Performance and Market Development - The company reported a main revenue of 239 million yuan in Q1 2025, an increase of 4.62% year-on-year, with a net profit of approximately 40.36 million yuan, reflecting a slight increase of 0.01% [10]. - The company has successfully registered key traditional Chinese medicine products in Singapore, marking a significant step in its international expansion strategy [2]. - The five key traditional Chinese medicine products saw a revenue increase of 24.49% year-on-year in Q1 2025, with the product Gan Zhi Bing Mei Pian experiencing a remarkable growth of 38.84% during the same period [5][6]. Group 2: Research and Development - The company has integrated its research capabilities through the acquisition of a controlling stake in Chengdu Aorui Pharmaceutical, enhancing its innovative drug development pipeline with seven ongoing projects targeting various cancers and autoimmune diseases [3][4]. - The lead project, ORIC-1940, is currently in clinical Ia/Ib trials and is positioned to be the first innovative drug for secondary hemophagocytic lymphohistiocytosis (HLH) in China [3][9]. - The company has established multiple R&D platforms and has applied for 35 patents, including 17 PCT patents, demonstrating its commitment to innovation [4]. Group 3: Product Strategy and Market Positioning - The company is focusing on the re-development of its key traditional Chinese medicine products, which are positioned in high-potential therapeutic areas, and has successfully extended the protection period for two of its products by seven years [5][7]. - The company is enhancing its market access strategies by promoting its products through academic channels and guidelines, which has led to 32 endorsements from authoritative sources [6][7]. - The sales distribution remains heavily weighted towards public hospitals, with approximately 70% of sales occurring in-hospital, while the company is also expanding its presence in retail and e-commerce channels [8]. Group 4: Special Medical Foods - The company has developed four self-researched special medical food projects, with one product recently receiving regulatory approval, marking a significant entry into this market segment [9]. - The company is actively working on the production and market launch of its special medical foods, leveraging digital marketing strategies to enhance product visibility [9].

（文章来源：每日经济新闻） 华森制药（SZ 002907，收盘价：18.71元）发布公告称，2025年8月5日，华森制药接受太平洋证券调 研，公司证券事务代表周智如等人参与接待，并回答了投资者提出的问题。 2024年1至12月份，华森制药的营业收入构成为：医药工业占比84.02%，医药商业占比14.36%，其他业 务占比1.38%，医药零售占比0.24%。 ...

Group 1: Company Performance and Market Development - The company has achieved significant breakthroughs in overseas markets, with its fifth production base passing the FDA's cGMP inspection in May 2023, establishing a high standard for its GMP management system [2][3] - Key traditional Chinese medicine products have received registration approvals in Singapore, marking a milestone for the company's international product pipeline [3] - Revenue from the five key traditional Chinese medicine products increased by 24.49% year-on-year in Q1 2025, with 甘桔冰梅片 showing a remarkable growth of 54.36% [6][7] Group 2: Research and Development Progress - The company has integrated its R&D capabilities through a majority stake in Chengdu Aorui Pharmaceutical, enhancing its small molecule innovative drug development capacity [4] - Currently, there are 7 innovative drug projects in the pipeline, targeting various cancers and autoimmune diseases, with the lead project ORIC-1940 in clinical trials [4][5] - The company has filed 35 patents, including 17 PCT patents, demonstrating its commitment to innovation [5] Group 3: Product Strategy and Market Positioning - The company is actively working on extending the protection period for its key traditional Chinese medicine products, with two products receiving a 7-year extension [6] - The company has received 32 recommendations from authoritative sources, reflecting the clinical and market value of its products [7] - The sales distribution remains heavily focused on public hospitals, with approximately 70% of sales occurring in-hospital, while efforts are being made to expand into retail and e-commerce channels [8][9] Group 4: Special Medical Foods and Future Plans - The company has four self-researched special medical food projects, with one project recently receiving regulatory approval, marking a significant entry into this market [10] - The company is exploring digital marketing strategies through various online platforms to enhance product visibility and sales [10] Group 5: Clinical Trials and Future Expectations - The company anticipates data from the ORIC-1940 clinical trial in 2024, with expectations for it to address safety concerns associated with existing therapies [11] - The board is considering implementing an equity incentive plan based on the company's development and market conditions [12]